Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Thursday, AstraZeneca Plc (NASDAQ:AZN) reported first-quarter sales of $12.68 billion, up 17% year over year (+19% at constant currency), slightly below the consensus of $11.83 billion.
This was fueled by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines.
The company’s adjusted EPADS reached $1.03, missing the consensus of $1.22.
Also Read: AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO’s Pay Package Boost.
R&D expenses rose about 18% to $2.7 billion, while sales, general, and administration costs were up 13% on higher marketing spend for new drug launches.
AstraZeneca’s top business, oncology, delivered a 26% jump in first-quarter sales to $5.12 billion.
Cardiovascular, Renal, and Metabolism (CVRM) sales increased 20% (up 23 at CER)% to $3.1 billion.
R&I Respiratory & Immunology sales increased 15% (17% CER).
Rare Disease drug sales increased by 12% (+16% at CER) to $2.1 billion.
Guidance: For fiscal year 2024, AstraZeneca reaffirms total revenues and core EPS are expected to increase by a low double-digit to low teens percentage at constant exchange rates.
Price Action: At the last check Thursday, AZN shares were up 4.99% at $74.75 during the premarket session.
Photo by Paul McManus via Pixabay
Posted In: AZN